Peter Lawson

Brian Abrahams

Colleen Hanley

Edward White

Jonathan Chang

Maurice Raycroft

Albert Agustinus

Colleen Kusy

Edward Tenthoff

Maury Raycroft

Ted Tenthoff

Yichun Qian

- Karyopharm announced strategic financing transactions expected to provide **$100 million** of financial flexibility and additional capital, extending its cash runway into the **second quarter of 2026**.  **[1503802_0001193125-25-233983_d940170dex991.htm:0]**  These transactions include **$27.5 million** in new term loan borrowings and new convertible notes, **$25 million** in near-term deferrals, a **$15 million** temporary reduction in the liquidity covenant, and **$8.75 million** in gross proceeds from a private placement.  **[1503802_0001193125-25-233983_d940170dex991.htm:0]** **[1503802_0001193125-25-233983_d940170d8k.htm:1]** 
- The company expects preliminary total revenue for the third quarter of 2025 to be in the range of **$42 million to $44 million**, with U.S. XPOVIO net product revenue approximately **$32 million**.  **[1503802_0001193125-25-233983_d940170dex991.htm:0]** **[1503802_0001193125-25-233983_d940170dex991.htm:1]** 
- As of **September 30, 2025**, Karyopharm expects to report approximately **$46 million** in cash, cash equivalents, restricted cash, and investments, prior to receiving approximately **$36 million** in gross proceeds from the financing transactions.  **[1503802_0001193125-25-233983_d940170dex991.htm:1]** **[1503802_0001193125-25-233983_d940170d8k.htm:1]** 
- Key clinical trial readouts are anticipated for the Phase 3 SENTRY trial in myelofibrosis in **March 2026** and the Phase 3 XPORT-EC-042 trial in endometrial cancer in **mid-2026**.  **[1503802_0001193125-25-233983_d940170dex991.htm:0]** **[1503802_0001193125-25-233983_d940170dex991.htm:1]**

Karyopharm Announces Strategic Financing and Preliminary Q3 2025 Results

- Karyopharm Therapeutics announced **strategic financing and capital structure transactions** expected to provide **$100 million** of financial flexibility and additional capital, extending its **cash runway into the second quarter of 2026**.  **[1503802_20251008NE92939:0]** 
- The financing includes **$67.5 million** in new term loan borrowings, new convertible notes, deferrals of interest and royalty payments, and a reduction in the minimum liquidity covenant, along with exchanges of existing convertible notes for common stock or pre-funded warrants.  **[1503802_20251008NE92939:0]** 
- The company also entered into a private placement for **1,487,917 shares of common stock** and warrants, expected to generate **approximately $8.75 million** in gross proceeds.  **[1503802_20251008NE92939:0]** 
- Preliminary financial results for the **third quarter of 2025** indicate total revenue in the range of **$42 million to $44 million** and U.S. XPOVIO net product revenue of approximately **$32 million**.  **[1503802_20251008NE92939:1]** 
- As of **September 30, 2025**, prior to receiving proceeds from the financing, Karyopharm expects to report **approximately $46 million** in cash, cash equivalents, restricted cash, and investments.  **[1503802_20251008NE92939:1]**

Karyopharm Therapeutics (KPTI)